Intra cellular Therapies Inc (ITCI) - News Archive

Showing 9 of 9 results.

Intra-Cellular Therapies Expands Portfolio with Strategic Acquisition, Reports Promising CAPLYTA Study Results at ACNP Annual Meeting

Breaking News: Intra-Cellular Therapies Announces Acquisition of CAPLYTA; Shares Surge Following Positive Phase 3 FindingsDate: December 11, 2024Intra-Cellular Therapies Inc. (NASDAQ: ITCI), a leading biopharmaceutical...

Jan 13, 2025 • Major Pharmaceutical Preparations Industry Merger and Acquisition

Intra-Cellular Therapies Reports Key Findings from CAPLYTA MDD Phase 3 Studies at ACNP Annual Meeting,

Intra-Cellular Therapies Inc recently presented compelling new data from its CAPLYTA (lumateperone) adjunctive therapy programme for major depressive disorder (MDD) at the annual meeting of the American College of Neuro...

Dec 30, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

Augmenting Psychiatric Care Lumateperone Demonstrates Promising Results in Schizophrenia and Major Depress...

: The recent advancements in the pharmacological management of schizophrenia and major depressive disorder (MDD) mark a significant milestone in psychiatric medicine. Lumateperone, marketed as CAPLYTA, has demonstrated...

Nov 5, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

Intra-Cellular Therapies Strengthens Leadership Team with New CFO Appointment

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a renowned biopharmaceutical company specializing in the development and commercialization of therapeutics for central nervous system (CNS) disorders, has recently announce...

Aug 7, 2024 • Major Pharmaceutical Preparations Industry Management Changes

Lumateperone Shows Promise as Adjunctive Therapy for Major Depressive Disorder A Positive Phase 3 Trial Evaluation

CSIMarket.com is excited to announce the significant findings of Study 502, conducted by Intra-Cellular Therapies, which evaluated the efficacy of lumateperone as an adjunctive therapy in patients with Major Depressive...

Jun 18, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

Intra-Cellular Therapies Presents Revolutionary Data at ASCP Annual Meeting, Demonstrates Strong Revenue Growth

Intra-Cellular Therapies Unveils Groundbreaking Data at ASCP Annual MeetingIntra-Cellular Therapies, Inc. (ITCI), a leading biopharmaceutical company specializing in therapeutics for central nervous system (CNS) disorde...

May 23, 2024 • Major Pharmaceutical Preparations Industry Product Service News

Intra-Cellular Therapies Raises $500 Million in Public Stock Offering for CNS Therapeutic Development and Commercialization

Intra-Cellular Therapies Prices Public Offering of Common Stock at $73 per share, Proceeds Expected to Reach $500 MillionIntra-Cellular Therapies, a biopharmaceutical company specializing in CNS disorders, recently anno...

Apr 18, 2024 • Major Pharmaceutical Preparations Industry Shares

Game-Changing Antidepressant Drug Lumateperone Sets New Standards: Intra-Cellular Therapies Posts Staggering 75.56% YoY Revenue Growth

Major depressive disorder (MDD) is a debilitating condition affecting over 264 million people worldwide, causing serious disruption to daily practices and inducing a significant burden on the world s healthcare system....

Apr 16, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

Intra-Cellular Therapies Announces Reshuffling of Executive Positions to Drive Growth and Innovation

Intra-Cellular Therapies, a renowned biopharmaceutical company specializing in the development and commercialization of therapeutics for central nervous system (CNS) disorders, has made significant changes in its leader...

Mar 19, 2024 • Major Pharmaceutical Preparations Industry Management Changes